Perioperative beta-Blockers for Cardiac Risk Reduction Time for Clarity

Division of General Internal Medicine, University of Michigan Health System, Ann Arbor, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 02/2010; 303(6):551-2. DOI: 10.1001/jama.2010.68
Source: PubMed

ABSTRACT Perioperative cardiac events are common and thought to result from coronary plaque rupture, myocardial oxygen supply-demand mismatch, or a combination of these processes.1 In theory, β-blockers are ideal for preventing these events, because they decrease myocardial oxygen requirements (by lowering heart rate and reducing blood pressure) and are thought to stabilize atherosclerotic plaque.2 However, perioperative β-blockade has become controversial because of conflicting results of recent studies. Based on the latest evidence, the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) restricted the once-broad class I indication for perioperative β-blockers to only patients already receiving this therapy.3 Why has the evidence not provided clarity?

Download full-text


Available from: Vineet Chopra, Jun 06, 2014
21 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endovascular aneurysm repair (EVAR), has surpassed open repair as the technique of choice in many centres in response to several large studies which showed significantly improved 30-day mortality. While several multicentre EVAR trials looked at surgical outcomes, very few have specifically investigated the effect of anaesthetic techniques or perioperative care of these patients. The purpose of this review to is to present some of the current evidence for the different aspects of perioperative management of patients undergoing EVAR. This includes surgical considerations, pre-operative assessment, and choice of anaesthetic technique as well as pharmacological protective strategies.
    Acta Anaesthesiologica Scandinavica 05/2012; 56(8):941-9. DOI:10.1111/j.1399-6576.2012.02681.x · 2.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Numerous risk factors have been identified for perioperative stroke, but there are conflicting data regarding the role of β adrenergic receptor blockade in general and metoprolol in particular. Methods: The authors retrospectively screened 57,218 consecutive patients for radiologic evidence of stroke within 30 days after noncardiac procedures at a tertiary care university hospital. Incidence of perioperative stroke within 30 days of surgery and associated risk factors were assessed. Patients taking either metoprolol or atenolol were matched based on a number of risk factors for stroke. Parsimonious logistic regression was used to generate a preoperative risk model for perioperative stroke in the unmatched cohort. Results: The incidence of perioperative stroke was 55 of 57,218 (0.09%). Preoperative metoprolol was associated with an approximately 4.2-fold increase in perioperative stroke (P < 0.001; 95% CI, 2.2-8.1). Analysis of matched cohorts revealed a significantly higher incidence of stroke in patients taking preoperative metoprolol compared with atenolol (P = 0.016). However, preoperative metoprolol was not an independent predictor of stroke in the entire cohort, which included patients who were not taking β blockers. The use of intraoperative metoprolol was associated with a 3.3-fold increase in perioperative stroke (P = 0.003; 95% CI, 1.4-7.8); no association was found for intraoperative esmolol or labetalol. Conclusions: Routine use of preoperative metoprolol, but not atenolol, is associated with stroke after noncardiac surgery, even after adjusting for comorbidities. Intraoperative metoprolol but not esmolol or labetalol, is associated with increased risk of perioperative stroke. Drugs other than metoprolol should be considered during the perioperative period if β blockade is required.
    Anesthesiology 04/2013; 119(6). DOI:10.1097/ALN.0b013e318295a25f · 5.88 Impact Factor
  • 08/2014; 16(3):71-77. DOI:10.1080/22201173.2010.10872685